Gary J Kelloff

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
  2. ncbi request reprint The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
  3. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
  4. doi request reprint Cancer biomarkers: selecting the right drug for the right patient
    Gary J Kelloff
    National Cancer Institute, Cancer Imaging Program, EPN Rm 6058, 6130 Executive Blvd, Bethesda, Maryland 20852, USA
    Nat Rev Drug Discov 11:201-14. 2012
  5. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
  6. ncbi request reprint Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005
  7. ncbi request reprint New science-based endpoints to accelerate oncology drug development
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Cancer Institute, Executive Plaza North Room 6038, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Eur J Cancer 41:491-501. 2005
  8. ncbi request reprint Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development
    Gary J Kelloff
    National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Executive Plaza North Room 6058, 6130 Executive Boulevard, Rockville, Maryland 20852, USA
    Nat Rev Cancer 7:508-18. 2007
  9. ncbi request reprint Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer
    Gary J Kelloff
    Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3927-33. 2004
  10. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007

Detail Information

Publications27

  1. ncbi request reprint Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development
    Joyce A O'Shaughnessy
    Baylor Sammons Cancer Center, US Oncology, Collins 5, 3535 Worth Street, Dallas, TX 75246, USA
    Clin Cancer Res 8:314-46. 2002
    ..The IEN Task Force proposes several clinical trial designs that provide practical and feasible approaches to the rapid development of new agents to treat and prevent precancer...
  2. ncbi request reprint The progress and promise of molecular imaging probes in oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Clin Cancer Res 11:7967-85. 2005
    ..The current regulatory opportunities for new and existing probe development and testing are also reviewed, with a focus on recent Food and Drug Administration guidance to facilitate early clinical development of promising probes...
  3. pmc Considerations in the development of circulating tumor cell technology for clinical use
    David R Parkinson
    New Enterprise Associates, Menlo Park, CA 94025, USA
    J Transl Med 10:138. 2012
    ....
  4. doi request reprint Cancer biomarkers: selecting the right drug for the right patient
    Gary J Kelloff
    National Cancer Institute, Cancer Imaging Program, EPN Rm 6058, 6130 Executive Blvd, Bethesda, Maryland 20852, USA
    Nat Rev Drug Discov 11:201-14. 2012
    ..Furthermore, we look ahead to the promises and challenges in the field of cancer biomarkers...
  5. ncbi request reprint Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward
    Gary J Kelloff
    National Cancer Institute, Bethesda, Maryland 20852, USA
    Clin Cancer Res 12:3661-97. 2006
    ....
  6. ncbi request reprint Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development
    Gary J Kelloff
    Cancer Imaging Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 11:2785-808. 2005
    ....
  7. ncbi request reprint New science-based endpoints to accelerate oncology drug development
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Cancer Institute, Executive Plaza North Room 6038, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Eur J Cancer 41:491-501. 2005
    ....
  8. ncbi request reprint Assessing intraepithelial neoplasia and drug safety in cancer-preventive drug development
    Gary J Kelloff
    National Institutes of Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis, Executive Plaza North Room 6058, 6130 Executive Boulevard, Rockville, Maryland 20852, USA
    Nat Rev Cancer 7:508-18. 2007
    ....
  9. ncbi request reprint Prostate-specific antigen doubling time as a surrogate marker for evaluation of oncologic drugs to treat prostate cancer
    Gary J Kelloff
    Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3927-33. 2004
  10. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  11. ncbi request reprint Colorectal adenomas: a prototype for the use of surrogate end points in the development of cancer prevention drugs
    Gary J Kelloff
    Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3908-18. 2004
  12. pmc Challenges in clinical prostate cancer: role of imaging
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, Cancer Imaging Program, National Institutes of Health, National Cancer Institute, Bethesda, MD 20852, USA
    AJR Am J Roentgenol 192:1455-70. 2009
    ..The workshop dealt with research trends and avenues for improving imaging and applications across the clinical spectrum of the disease...
  13. ncbi request reprint Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers
    Gary J Kelloff
    National Cancer Institute, Division of Cancer Treatment and Diagnosis, Biomedical Imaging Program, Bethesda, Maryland 20892, USA
    Cancer Epidemiol Biomarkers Prev 12:593-6. 2003
  14. ncbi request reprint Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue
    Gary J Kelloff
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 10:3881-4. 2004
  15. doi request reprint Targeted imaging: an important biomarker for understanding disease progression in the era of personalized medicine
    William C Eckelman
    Molecular Tracer LLC, Bethesda, MD 20814, USA
    Drug Discov Today 13:748-59. 2008
    ..Such an imaging agent developed in concert with drug development has a built in synergy that will accelerate the drug development process, targeted imaging and personalized medicine as well...
  16. ncbi request reprint Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy
    James L Tatum
    National Cancer Institute, Executive Plaza North, Room 6000, 6130 Executive Boulevard, Rockville, MD 20852 7440, USA
    Int J Radiat Biol 82:699-757. 2006
    ....
  17. ncbi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....
  18. ncbi request reprint FDG-PET lymphoma demonstration project invitational workshop
    Gary J Kelloff
    National Institutes of Health NIH National Cancer Institute NCI Division of Cancer Treatment and Diagnosis DCTD Cancer Imaging Program, Bethesda, MD, USA
    Acad Radiol 14:330-9. 2007
    ....
  19. ncbi request reprint Development of cancer chemopreventive drugs based on mechanistic approaches
    Vernon E Steele
    National Cancer Institute, EPN 2108, MSC 7322, 9000 Rockville Pike, National Institutes of Health, Bethesda, MD 20892 7322, USA
    Mutat Res 591:16-23. 2005
    ..Each cancer type, organ location, or individual genetic background may require a custom combination of prevention strategies to be successful...
  20. ncbi request reprint Imaging and oncologic drug development
    Wafik S El-Deiry
    Department of Medicine Hematology Oncology, The Abramson Comprehensive Cancer Center, and the Institute for Translational Medicine and Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Oncol 24:3261-73. 2006
    ....
  21. ncbi request reprint Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development
    John W Park
    University of California, San Francisco Cancer Center, San Francisco, California 94115 1710, USA
    Clin Cancer Res 10:3885-96. 2004
  22. ncbi request reprint Reanalysis of cancer drugs: old drugs, new tricks
    George F Vande Woude
    Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Clin Cancer Res 10:3897-907. 2004
  23. ncbi request reprint Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer
    Gordon J S Rustin
    Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, United Kingdom
    Clin Cancer Res 10:3919-26. 2004
  24. ncbi request reprint Regulatory and reimbursement challenges for molecular imaging
    John M Hoffman
    Department of Radiology, University of Utah School of Medicine, 2000 Circle of Hope, Suite 2121, Salt Lake City, UT 84112 5550, USA
    Radiology 245:645-60. 2007
    ....
  25. ncbi request reprint N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
    Ann Marie Simeone
    Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Carcinogenesis 26:1000-7. 2005
    ..These in vitro results suggest that 4-HPR may be an effective chemopreventive agent against breast tumors that exhibit BRCA1 mutations because of its ability to induce NO-mediated apoptosis in such tumors...
  26. ncbi request reprint Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites
    Anita L Sabichi
    Department of Clinical Cancer Prevention, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:4606-13. 2003
    ..Thus, 4-MPR may play a role in the clinical activity of 4-HPR. This study further reveals the mechanism of action of these novel phenylretinamides and supports continued investigation into their development as chemopreventive drugs...
  27. ncbi request reprint 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats
    Konstantin T Christov
    Department of Surgical Oncology, College of Medicine, University of Illinois, 840 South Wood Street MC 820, Chicago, IL 60612, USA
    Cancer Res 62:5178-82. 2002
    ....